The conversation is about finding a source for topical valproic acid for hair regrowth. The user mentions PP405 and the unavailability of products from certain suppliers.
The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
The conversation discusses using a microneedling device on the face after using it on the scalp, with suggestions to use a depth of 0.2mm for facial treatments. Caution and proper sterilization are advised due to the sensitivity of facial skin.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.
A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.
Use rosemary oil 2-3 times a week, ideally after derma rolling, for optimal results. This routine can complement other treatments like Minoxidil, finasteride, or RU58841.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."
Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.
A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.
The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation is about the effectiveness of Maneup GHK-Cu hair growth serum, a topical treatment for hair loss. The user is considering trying it but is skeptical due to issues others have had with DIY injections of a similar substance.
A 45-year-old user shared progress pictures after 4 months of using a topical gel with 2.5% finasteride and 5% minoxidil once daily. The second picture shows significant improvement in hair growth.
Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
OP asked if a product from Amazon is sufficient to dilute finasteride. A user advised against using propylene glycol alone, suggesting a pre-made solution instead.
A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
The conversation is about using a trivitamin oil mix (Vitamin E, D3, A, Argan Oil, Sunflower Oil) for hair thinning and whether it is safe to apply it after derma rolling. It is advised to wait 12-24 hours after derma rolling before applying any products to avoid infections or allergic reactions.
The conversation discusses hair regrowth using saw palmetto (800 mg daily), a derma roller (0.5 mm twice a week), rosemary oil, and a multivitamin. The user mentions using Bliss Pharma's saw palmetto supplement.
A user is using a topical spray containing Finasteride 1% and Minoxidil 5% along with other ingredients like glycerin and aqua, questioning if these are effective carrier agents. They apply it once daily and use a separate 5% Minoxidil solution at night.
The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.